StockNews.AI
UBX
StockNews.AI
119 days

UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

1. UBX1325 showed early vision improvements in diabetic macular edema patients. 2. Study didn't meet primary endpoint but was non-inferior at week 36. 3. Company's cash position can sustain operations into Q4 2025. 4. Net loss increased to $7.3 million from $5.8 million year-on-year. 5. Full 36-week data is expected in Q2 2025, crucial for future studies.

10m saved
Insight
Article

FAQ

Why Bullish?

Despite missing primary endpoints, UBX1325 shows promise with interim non-inferiority results. Historical examples show similar scenarios sometimes boost stocks if future potential is recognized.

How important is it?

Ongoing clinical studies and interim results can significantly alter market perception of UBX. The expected data release could lead to more concrete assessments of the therapy's viability.

Why Short Term?

The announcement of new data in Q2 may trigger immediate investor interest and stock price movement.

Related Companies

VRTXEXASREGN
SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2025. UNITY announced 24-week and partial 36-week topline data from our Phase 2b ASPIRE study in diabetic macular edema (DME) in the first quarter. DME patients treated with UBX1325 (foselutoclax) showed vision improvements generally comparable to the aflibercept control, but the study did not meet the primary endpoint of statistical non-inferiority to aflibercept based on BCVA average at weeks 20 and 24. UBX1325 was non-inferior to aflibercept at week 36, based on interim data. "The 24-week data indicates that UBX1325, acting via a novel mechanism of action, can lead to vision improvement in patients with inadequate response to standard of care," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "The full 36-week data will be instrumental in shaping our plans for subsequent studies.” UNITY anticipates receiving the full 36-week data in the second quarter of 2025. The Phase 2b ASPIRE study in DME is a multi-center, randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 in a head-to-head comparison to aflibercept. More information about ASPIRE (NCT06011798) can be found here. First Quarter Financial Results Cash, cash equivalents and marketable securities totaled $16.9 million as of March 31, 2025 compared with $23.2 million as of December 31, 2024. UNITY believes that current cash, cash equivalents and marketable securities are sufficient to fund operations into the fourth quarter of 2025. Net loss for the three months ended March 31, 2025 was $7.3 million compared to $5.8 million for the three months ended March 31, 2024. Cash used in operations during the three months ended March 31, 2025 was $6.4 million compared to $5.2 million for the three months ended March 31, 2024. Research and development expenses decreased by $0.9 million, to $2.9 million for the three months ended March 31, 2025 from $3.7 million for the three months ended March 31, 2024. The decrease was primarily due to decreases of $0.5 million in direct research and development expenses mainly due to the near completion of the Phase 2 ASPIRE study of UBX1325 in patients with DME in the first half of 2025 and $0.4 million in personnel costs due to our reduced headcount. General and administrative expenses increased by $0.2 million, to $4.0 million for the three months ended March 31, 2025 from $3.9 million for the three months ended March 31, 2024. The increase was primarily due to an increase of $0.2 million in professional fees and accounting service fees and $0.2 million in operating costs mainly from reduced sublease income, partially offset by a decrease of $0.2 million in personnel-related expenses due to reduced headcount and the reduction in stock based compensation expense compared to amounts incurred in the same period in 2024. About UNITY UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on X and LinkedIn. Forward-Looking StatementsThis press release contains forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to slow, halt, or reverse diseases of aging, including for ophthalmologic and neurologic diseases, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for DME, AMD, and other ophthalmologic diseases, the expected timing of enrollment and results of the clinical trials in UBX1325, and UNITY’s expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements, including risks related to delay or disruption in the enrollment of patients in clinical trials, risks relating to the uncertainties inherent in the drug development process, and risks relating to UNITY’s understanding of senescence biology. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see UNITY’s most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission on April 22, 2025, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.     Unity Biotechnology, Inc.Statements of Operations and Comprehensive Loss(In thousands, except share and per share amounts)      Three Months Ended   March 31,   2025  2024   (Unaudited) Operating expenses:      Research and development $2,772  $3,721 General and administrative  4,119   3,878 Total operating expenses  6,891   7,599 Loss from operations  (6,891)  (7,599)Interest income  260   513 (Loss) gain on warrant liability  (610)  1,376 Other expense, net  (61)  (80)Net loss  (7,302)  (5,790)Other comprehensive loss      Unrealized loss on marketable debt securities  (14)  (14)Comprehensive loss $(7,316) $(5,804)Net loss per share, basic and diluted $(0.43) $(0.34)Weighted-average number of shares used in computing net loss per share, basic and diluted  16,870,800   16,785,090                  Unity Biotechnology, Inc.Condensed Balance Sheets(In thousands)         March 31,  December 31,   2025  2024   (Unaudited)    Assets      Current Assets:      Cash and cash equivalents $7,999  $7,580 Short-term marketable securities  8,934   15,650 Prepaid expenses and other current assets  714   1,037 Total current assets  17,647   24,267 Property and equipment, net  3,278   3,456 Operating lease right-of-use assets  8,455   8,900 Long-term restricted cash  896   896 Other long-term assets  71   143 Total assets $30,347  $37,662 Liabilities and Stockholders’ Equity      Current liabilities:      Accounts payable $1,761  $997 Accrued compensation  1,241   2,096 Accrued and other current liabilities  6,064   6,167 Total current liabilities  9,066   9,260 Operating lease liability, net of current portion  18,677   19,709 Warrant liability  2,809   2,199 Total liabilities  30,552   31,168 Commitments and contingencies      Stockholders’ (deficit) equity:      Common stock  2   2 Additional paid-in capital  517,437   516,820 Accumulated other comprehensive income  1   15 Accumulated deficit  (517,645)  (510,343)Total stockholders’ (deficit) equity  (205)  6,494 Total liabilities and stockholders’ (deficit) equity $30,347  $37,662           Media Inizio Evoke CommsKatherine Smithkatherine.smith@inizioevoke.com Investor Contact LifeSci Advisors, LLCJoyce Allairejallaire@lifesciadvisors.com

Related News